Feb 07, 2018 - On Jan. 31, I published an article on three biotech catalysts to watch in February; this article adds another one to the list.On Feb. 17, Apricus Biosciences will get the FDA verdict on Vitaros, a top
Feb 07, 2018 - Allergan scores supplemental approval for hospital-acquired infection.Spectrum scores on efficacy in a supportive care study.AMAG Pharmaceuticals scores supplemental approval for Feraheme.
Feb 07, 2018 - Nabriva has a major catalyst coming up. GW Pharmaceuticals’ marketing application for Epidiolex accepted by EMA. ContraVir announces results from early stage study of Hep B candidate TXL.
Feb 07, 2018 - Mayo Investment Advisers Llc Buys Schlumberger, Sells Hess Corp, Allergan PLC, Acacia Communications Inc, Stocks: SLB,HES,AGN,ACIA,GOOGL,C,AAPL,NWL,T,GPOR,CTSH,GM,G, release date:Feb 07, 2018
Feb 07, 2018 - U.S. stock index futures dropped deep into the red again overnight, pulling back from the roller coaster ride in the previous session that saw the DJIA close up 567 points following two major selloff
Feb 06, 2018 - Allergan ended 2017 on a solid note, but guides for declining sales in 2018.This is concerning as it takes longer for the pipeline to translate into growth as leverage remains high.While shares look c
Feb 06, 2018 - Allergan Plc (NYSE:AGN)Q4 2017 Earnings CallFebruary 06, 2018 8:30 am ETExecutivesDaphne Karydas - Allergan PlcBrenton L. Saunders - Allergan PlcWilliam J. Meury - Allergan PlcC. David Nicholson - All
Feb 06, 2018 - The following slide deck was published by Allergan plc in conjunction with their 2017 Q4 earnings call.
Feb 06, 2018 - Allergan (AGN) beats expectations for both earnings and revenues in Q4. A phase III study evaluating Allergan's migraine candidate, ubrogepant meets its co-primary endpoints.
Feb 06, 2018 - AMAG got a nod for label expansion for Feraheme from the FDA. Bristol-Myers Squibb’s Q4 results beat expectations. EyeGate tumbles as lead candidate fails.